WO2001047468A3 - Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase - Google Patents

Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase Download PDF

Info

Publication number
WO2001047468A3
WO2001047468A3 PCT/FR2000/003605 FR0003605W WO0147468A3 WO 2001047468 A3 WO2001047468 A3 WO 2001047468A3 FR 0003605 W FR0003605 W FR 0003605W WO 0147468 A3 WO0147468 A3 WO 0147468A3
Authority
WO
WIPO (PCT)
Prior art keywords
association
deoxyfructosazine
antidiabetic
glucosidase
inhibiting alpha
Prior art date
Application number
PCT/FR2000/003605
Other languages
English (en)
Other versions
WO2001047468A2 (fr
Inventor
Michel Evers
Original Assignee
Aventis Pharma Sa
Michel Evers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Michel Evers filed Critical Aventis Pharma Sa
Priority to AU26878/01A priority Critical patent/AU2687801A/en
Publication of WO2001047468A2 publication Critical patent/WO2001047468A2/fr
Publication of WO2001047468A3 publication Critical patent/WO2001047468A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'association de déoxyfructosazine et d'un antidiabétique inhibiteur d'alpha-glucosidase, les compositions pharmaceutiques contenant cette association et leur utilisation dans la prévention et/ou le traitement du diabète de type 2 et ses complications.
PCT/FR2000/003605 1999-12-23 2000-12-20 Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase WO2001047468A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26878/01A AU2687801A (en) 1999-12-23 2000-12-20 Association of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9916360A FR2802816A1 (fr) 1999-12-23 1999-12-23 Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase
FR99/16360 1999-12-23

Publications (2)

Publication Number Publication Date
WO2001047468A2 WO2001047468A2 (fr) 2001-07-05
WO2001047468A3 true WO2001047468A3 (fr) 2002-11-28

Family

ID=9553733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/003605 WO2001047468A2 (fr) 1999-12-23 2000-12-20 Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase

Country Status (3)

Country Link
AU (1) AU2687801A (fr)
FR (1) FR2802816A1 (fr)
WO (1) WO2001047468A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766183A1 (fr) * 1997-07-17 1999-01-22 Rhone Poulenc Rorer Sa Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766183A1 (fr) * 1997-07-17 1999-01-22 Rhone Poulenc Rorer Sa Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHARBONNEL B.: "[Current management strategies in type 2 diabetes]. STRATEGIES ACTUELLES DE PRISE EN CHARGE DU DIABETE DE TYPE 2.", DISEASE MANAGEMENT AND HEALTH OUTCOMES, (1998) 4/SUPPL. 1 (13-28)., XP000949819 *

Also Published As

Publication number Publication date
WO2001047468A2 (fr) 2001-07-05
FR2802816A1 (fr) 2001-06-29
AU2687801A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
CA2267186A1 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
CA2340052A1 (fr) Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO1999054286A3 (fr) Inhibiteurs btk et leurs procedes d'identification et d'utilisation
HUP0103506A3 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors and pharmaceutical composition containing them
CA2257010A1 (fr) Methodes et compositions pour le traitement et la prevention des tumeurs, des troubles relies a des tumeurs et de la cachexie
AU6053900A (en) Compositions for treating or preventing neurodegeneration and cognitive decline
WO2000053583A8 (fr) Inhibiteurs de la tyrosine phosphatase
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
WO1999005096A3 (fr) Inhibiteurs d'urokinase
WO1999011606A3 (fr) Inhibiteurs de la proteine tyrosine phosphatase
YU34199A (sh) Primena inhibitora gastrointestinalne lipaze
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
CA2340728A1 (fr) Methodes de traitement de l'hypertension et compositions utiles a cet effet
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
CA2200126A1 (fr) Traitement et prophylaxie de la pancreatite
AU5773800A (en) Cleaning, laundering or treating compositions containing cross-linked hydrolase crystals
WO2001010408A3 (fr) Composition pharmaceutique aqueuse a base de moxifloxacine ou de ses sels
WO2002040016A3 (fr) Association d'inhibiteurs de calpaïne et de piegeurs des formes reactives de l'oxygene
WO2001002373A8 (fr) Dihydrobenzodiazepines et leur utilisation dans le traitement de dyslipidemies
WO2001066144A3 (fr) Therapie d'association de medicaments
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP